These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21474786)

  • 1. Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.
    Yin AY; Htun M; Swerdloff RS; Diaz-Arjonilla M; Dudley RE; Faulkner S; Bross R; Leung A; Baravarian S; Hull L; Longstreth JA; Kulback S; Flippo G; Wang C
    J Androl; 2012; 33(2):190-201. PubMed ID: 21474786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men.
    Yin A; Alfadhli E; Htun M; Dudley R; Faulkner S; Hull L; Leung A; Bross R; Longstreth J; Swerdloff R; Wang C
    J Androl; 2012; 33(6):1282-90. PubMed ID: 22790645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
    Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oral lipidic native testosterone formulation that is absorbed independent of food.
    Newell-Price J; Huatan H; Quirke J; Porter J; Daniel E; Mumdzic E; Voet B; Keevil B; Whitaker MJ; Ross RJ
    Eur J Endocrinol; 2021 Oct; 185(5):607-615. PubMed ID: 34379604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which testosterone replacement therapy?
    Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone undecanoate: a new orally active androgen.
    Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.
    Amory JK; Bush MA; Zhi H; Caricofe RB; Matsumoto AM; Swerdloff RS; Wang C; Clark RV
    J Urol; 2011 Feb; 185(2):626-32. PubMed ID: 21168874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.
    Lee A; Rubinow K; Clark RV; Caricofe RB; Bush MA; Zhi H; Roth MY; Page ST; Bremner WJ; Amory JK
    J Androl; 2012; 33(3):420-6. PubMed ID: 21868746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
    Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
    Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine and Serum Sex Steroid Profile in Testosterone-Treated Transgender and Hypogonadal and Healthy Control Men.
    Savkovic S; Lim S; Jayadev V; Conway A; Turner L; Curtis D; Goebel C; Handelsman DJ
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2277-2283. PubMed ID: 29584875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.